Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6702693 | 0.88 | CYP3A4 (0.34) | TSHRCYP3A4KDM4EGAAL3MBTL1 | |
| SCHEMBL3487495 | 0.88 | ALDH1A1 (0.41) | TSHRCYP3A4KDM4EGAAL3MBTL1 | |
| SCHEMBL3247412 | 0.85 | MAPK1 (0.43) | TSHRL3MBTL1MAPTALDH1A1KMT2A | |
| SCHEMBL29705142 | 0.85 | ATM (0.43) | L3MBTL1MAPTALDH1A1KMT2AHCAR3 | |
| SCHEMBL27475420 | 0.85 | TSHR (0.43) | TSHRCYP3A4L3MBTL1MAPTALDH1A1 | |
| SCHEMBL20521236 | 0.85 | ATM (0.43) | L3MBTL1MAPTALDH1A1KMT2AHCAR3 | |
| SCHEMBL3487106 | 0.85 | HSD17B1 (0.44) | KDM4EL3MBTL1MAPTALDH1A1KMT2A | |
| SCHEMBL15071643 | 0.84 | PDE7A (0.37) | GAAMAPTALDH1A1KMT2AHCAR3 | |
| SCHEMBL1131379 | 0.84 | MEN1 (0.44) | KDM4EMAPTALDH1A1KMT2APOLB | |
| SCHEMBL27804060 | 0.84 | L3MBTL1 (0.39) | TSHRCYP3A4KDM4EGAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946264-B2 | Pyridine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-02-03 | — | — | US | disclosed |
| US-20130045994-A1 | PYRIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-02-21 | — | — | US | disclosed |
| US-20120029026-A1 | PYRIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029026-A1 | PYRIDINE DERIVATIVE | PPARD, PPARG, PPARA | TSHR 195/4885CYP3A4 247/4885KDM4E 2695/4885 |
| US-20130045994-A1 | PYRIDINE DERIVATIVE | PPARD, PPARG, PPARA | TSHR 195/4885CYP3A4 247/4885KDM4E 2695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.